Seisa Medical Group, a manufacturer of FDA-approved class I, II, and III products, is increasing its capabilities as well as its engineering staff by acquiring Burpee MedSystem, said CEO Julio Chiu, during Mexico’s Manufacturing Supply Chain Summit organized by MexicoNow.
“Burpee MedSystem is a natural fit to supplement Seisa’s existing expertise in Class III implantable and catheter solutions,” Chiu highlighted.
Furthermore, this acquisition adds end-to-end, nitinol-based implantable stent delivery systems capability to Seia’s portfolio, aggregates capability and expertise for one stop solutions and incorporates a U.S-based solutions center.
Some of the product areas Burpee will add to Seisa’s portfolio includes: stents, catheters, balloon catheters, stent and implants delivery systems, guide catheters, introducers, dilators, closure devices, dialysis devices, stent and customized components, and delivery systems for any implant systems.
The financial details of the transaction were not disclosed.
The announcement comes one year after Seisa obtained a US$42.5-million senior secured credit facility with Sagard Credit Partners.
Based in Eatontown, New Jersey, Burpee Medsystems designs and fabricates stents and other neurovascular and coronary devices, including valve and steel components. The company also provides laser machining, wire forming, radiopaque marking, and electro-polishing services.
The company was founded in 1998 and is based in Eatontown, New Jersey.
Seisa Medical Group manufactures catheter-based products, implantable stents, tubing sets, pediatric, and orthopedic-care products. The company, founded in 1983, operates manufacturing facilities in Ciudad Juarez, Mexico, and Slovakia, while being based in El Paso, Texas.
Nancy Gonzalez / MexicoNow